Development and validation of RPLC method for the simultaneous analysis of ACE inhibitors in tablet formulations

Abstract

Hypertension is a disease that can progress for many years without symptoms or complications. This disease can cause death and permanent damage to vital organs such as the kidney, heart, and brain. However, when hypertension is treated effectively, these risk factors may decrease significantly. Although many antihypertensive drugs are used in the treatment of hypertension, ACE inhibitors are a new class among these drugs, and their separation and quantitative determinations are important for the success of preclinical, biopharmaceutical, and clinical studies. For this reason, in this study, the simultaneous determination of cilazapril, benazepril, and quinapril from ACE inhibitors, the validation of the developed method, and the quantitative determination of commercial drug dosage forms are aimed. To obtain the optimum liquid chromatographic separation condition, a systematic approach based on the relationship between mobile phase pH and retention time was used. The mobile phase organic modified concentration and column temperature parameters, which are known to affect the retention times of the compounds, were kept constant. When deciding on these parameters, few experiments were carried out.